Navigation Links
InterMune Reports Results from Triple Combination Study of ITMN-191
Date:1/12/2009

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. InterMune to Present at Thomas Weisel Partners Healthcare Conference
2. Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations
3. InterMune to Present at the 2008 Wachovia Healthcare Conference
4. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
5. LegalView Reports Traumatic Brain Injury Study Concluding Spirituality Increases Following Brain Damage
6. Allscripts Reports Fiscal 2009 Second Quarter Results
7. MDS Reports Final Fourth-Quarter 2008 Results
8. Consumer Reports: Big Promises of Some Infomercial Exercise Machines Fall Flat; Plus, Set Up a Home Gym for Under $100
9. Cardium Reports on Exchange Listing With NYSE Alternext US
10. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
11. Joint Commission Reports Positive Survey Results for CHA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the ... created for kids with cancer. The Chemo Duck App, available on ... with enjoyable games to help children of all ages living with ... to keep kids entertained, educated and at ease while waiting for ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... deaths from stroke in the US occur among postmenopausal women. ... women at risk be detected?// ,One way may ... sign of stroke risk is atheroma - fatty deposits in ... up through a dental x-ray. Researchers in California have assessed ...
... cancer should be screened periodically once in 5 years in ... blood test (FOBT) which looks for traces of blood shed ... the lower colon. According to researchers at the Finland Affairs ... has been decreased due to the routine screening.// ,They ...
... by mosquitoes.It is characterised by fever, chills,followed by excessive ... disease can lead to death even .This is a ... of this disease involves the control of breeding of ... spray the inside of their houses with insecticide to ...
... just provide a bridge to a transplant.Heart failure is characterised by ... the body. Till now, it has always been assumed that heart ... transplant.// ,The left ventricular assist device (LVAD) is a ... taking over some of its workload. It's used a bridge to ...
... animals, the nerve cells must communicate with the neurons by ... study, biologists from Utah showed how a single protein plays ... send these chemical signals. , The experimented animals were ... crippled the protein UNC-13. , " All our thoughts ...
... rates of heart disease and cancer, although few clinical studies have ... green tea in men with prostate cancer. They hope it will ... on the benefits of tea.// Generally tea drinkers are less ... still unknown. ,One likely reason is the high levels ...
Cached Medicine News:
(Date:1/23/2015)... 2015  MedScope ( www.medscope.org ), the leading provider of ... Connected World magazine Connected World Award for ... can be used anywhere, anytime. The nomination was made ... In nominating MedScope, Landon Garner , Director of ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... EAST SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology ... sites where its Phase I trial of Lixte,s lead compound, ... 5 institutions. John S. Kovach , M.D., ... trial was planned to be completed at a single site. ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... of its exclusive licensee in Japan after Itochu reaches ... for cosmeceutical and dietary supplement products using patented AC-11(R) ... fueled by results of new research showing that that ... III in the epidermis layer of the skin. , ...
... II Testing Certification with Edifecs CORE Testing Service - ... X12 Version 5010BELLEVUE, Wash., April 5 ... partners CAQH and Harvard Pilgrim Health Care, examine the ... Certification testing including elements of the newly mandated 5010 ...
Cached Medicine Technology:Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan 2Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan 3Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 2Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 3Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 4Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: